Skip to main content
SpringerLink
Log in

Molekulare Diagnostik bei nicht-hämatologischen malignen Erkrankungen

Molecular diagnostics in non-haematological malignancies

  • Weiterbildung · Zertifizierte Fortbildung
  • Published:
Der Onkologe Aims and scope

Zusammenfassung

Molekularbiologische Untersuchungen in der Tumordiagnostik haben sich in den letzten Jahren zu einem wesentlichen Bestandteil der pathologischen Routinediagnostik entwickelt. Gängige Untersuchungsmethoden, die sich auch für formalinfixiertes Gewebe eignen, sind die Polymerasekettenreaktion und die Fluoreszenz-in-situ-Hybridisierung. Die molekularen Analysen liefern zum einen Informationen, die die histologische und immunhistochemische Diagnostik ergänzen, z. B. durch den Nachweis charakteristischer Genveränderungen bei bestimmten Tumorentitäten. Darüber hinaus geben sie aber auch die Möglichkeit, Aussagen zur Prognose oder Therapie von Tumorerkrankungen zu treffen. In der vorliegenden Arbeit werden die zurzeit etablierten Methoden beschrieben und neue Entwicklungen, v. a. aus dem Bereich der Therapieprädiktion, aufgezeigt.

Abstract

Recently, the molecular diagnosis of tumours has developed into an integral part of routine pathological diagnosis. Common methods that are suitable for formalin-fixed tissue are the polymerase chain reaction and fluorescence in situ hybridization. Molecular data provide the pathologist with additional information, completing the histological and immunohistochemical diagnosis, for example for the analysis of characteristic chromosomal aberrations in certain tumour entities. Furthermore, parameters for tumour prognosis and therapeutic options are obtained by molecular analyses. This article describes the currently available methods in molecular pathology of non-haematological malignancies and presents new trends, especially in the field of predicting specific therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5
Abb. 6

Literatur

  1. Alizadeh AA, Eisen MB, Davis RE et al. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403: 503–511

    Google Scholar 

  2. Andersson LJ, Sjögren H, Meis-Kindblom JM, Stenman G, Aman P, Kindblom LG (2002) The complexity of KIT gene mutations and chromosome rearrangements and their clinical correlation in gastrointestinal stromal (pacemaker cell) tumors. Am J Pathol 160: 15–22

    Google Scholar 

  3. Corless CL, Fletcher JA, Heinrich MC (2004) Biology of gastrointestinal stromal tumors. J Clin Oncol 22: 3813–3825

    Google Scholar 

  4. De Alava E, Kawai A, Healey JH et al. (1998) EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing’s sarcoma. J Clin Oncol 16: 1248–1255

    Google Scholar 

  5. Duffy MJ (2002) Urokinase plasminogen activator and its inhibitor, PAI-1 as prognostic markers in breast cancer: from pilot to level I evidence studies. Clin Chem 48: 1194–1197

    Google Scholar 

  6. Fletcher CD, Berman J, Corless CL et al. (2002) Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 33: 459–465

    Google Scholar 

  7. Frolov A, Chahwan S, Ochs M et al. (2003) Response markers and the molecular mechanisms of action of Gleevec in gastrointestinal stromal tumors. Mol Cancer Ther 2: 669–709

    Google Scholar 

  8. Fukuoka M, Yano S, Giaccone G et al. (2003) Multi-institutional randomized phase II trial of gefintinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21: 2237–2246

    Google Scholar 

  9. Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, Gerald WL (2004) Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 113: 913–923

    Google Scholar 

  10. Heinrich MC, Corless CL, Demetri GD et al. (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21: 4342–4349

    Google Scholar 

  11. Heinrich MC, Corless CL, Duensing A et al. (2003) PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299: 708–710

    Google Scholar 

  12. Hill DA, Reidley SE, Patel AR et al. (2002) Real-time polymerase chain reaction as an aid for the detection of SYT-SSX1 and SYT-SSX2 transcripts in fresh and archival pediatric synovial sarcoma specimens: report of 25 cases from St. Jude Children’s Research Hospital. Pediatr Dev Pathol 6: 24–34

    Google Scholar 

  13. Hirota S, Nishida T, Isozaki K et al. (2001) Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumors. J Pathol 193: 505–510

    Google Scholar 

  14. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ (1999) Specifity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration — approved scoring system. J Clin Oncol 17: 1983–1987

    Google Scholar 

  15. Jennings BA, Hadfield JE, Worsley SD, Girling A, Willis G (1997) A differential PCR assay for the detection of c-erbB 2 amplification used in a prospective study of breast cancer. J Clin Pathol Mol Pathol 50: 254–256

    Google Scholar 

  16. Jones D, Fletcher CDM (1999) How shall we apply the new biology to diagnostics in surgical pathology? J Pathol 187: 147–154

    Google Scholar 

  17. Kawai A, Woodruff J, Healey JH, Brennan MF, Antonescu CR, Ladanyi M (1998) SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med 388: 153–160

    Google Scholar 

  18. Kumar S, Pack S, Kumar D et al. (1999) Detection of EWS-Fli1 fusion in Ewing’s sarcoma/peripheral primitive neuroectodermal tumor by fluorescence in situ hybridization using formalin-fixed paraffin-embedded tissue. Hum Pathol 30: 324–330

    Google Scholar 

  19. Ladanyi M, Bridge JA (2000) Contribution of molecular genetic data to the classification of sarcomas. Hum Pathol 31: 532–538

    Google Scholar 

  20. Lebeau A, Deimling D, Kaltz C et al. (2001) HER-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol 19: 354–363

    Google Scholar 

  21. Lehmann U, Glöckner S, Kleeberger W, Wasielewski HF von, Kreipe H (2000) Detection of gene amplification in archival breast cancer specimens by laser-assisted microdissection and quantitative real-time polymerase chain reaction. Am J Pathol 156: 1855–1864

    Google Scholar 

  22. Lynch HT, Chapelle A de la (2003) Hereditary colorectal cancer. N Engl J Med 348: 919–932

    Google Scholar 

  23. Lynch TJ, Bell DW, Sordella R et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129–2139

    Google Scholar 

  24. Markowitz S, Wang J, Myeroff L et al. (1995) Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science 268: 1336–1338

    Google Scholar 

  25. Mass RD, Sanders C, Johnson CL, Everett T, Anderson S (2000) The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridisation (FISH) in the Herceptin Pivotal Trials. Proc Am Soc Clin Oncol 19: 75a

    Google Scholar 

  26. Merkelbach-Bruse S, Wardelmann E, Behrens P, Losen I, Büttner R, Friedrichs N (2003) Current diagnostic methods of HER-2/neu detection in breast cancer with special regard to real-time PCR. Am J Surg Pathol 27: 1565–1570

    Google Scholar 

  27. Miettinen M, El-Rifai W, Sobin LH, Lasota J (2002) Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol 33: 478–483

    Google Scholar 

  28. Monforte-Munoz H, Lopez-Terrada D, Affendie H, Rowland JM, Triche TJ (1999) Documentation of EWS gene rearrangements by fluorescence in-situ hybridization (FISH) in frozen sections of Ewing’s sarcoma-peripheral primitive neuroectodermal tumor. Am J Surg Pathol 23: 309–315

    Google Scholar 

  29. O’Sullivan, Perlman EJ, Furman J, Humphrey PA, Dehner LP, Pfeifer JD (2001) Visceral primitive peripheral neuroectodermal tumors: a clinicopathologic and molecular study. Hum Pathol 32: 1109–1115

    Google Scholar 

  30. Paez JG, Jänne PA, Lee JC et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefintinib therapy. Science 304: 1497–1500

    Google Scholar 

  31. Perou CM, Sorlie T, Eisen MB et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747–752

    Google Scholar 

  32. Pfeifer JD, Hill DA, O’Sullivan MJ, Dehner LP (2000) Diagnostic gold standard for soft tissue tumours: morphology or molecular genetics. Histopathology 37: 485–500

    Google Scholar 

  33. Rodriguez-Bigas MA, Boland CR, Hamilton SR et al. (1997) A National Cancer Institute workshop on HNPCC syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 89: 1785–1762

    Google Scholar 

  34. Rüschoff J, Bocker T, Schlegel J, Stumm G, Hofstaedter F (1995) Microsatellite instability: new aspects in the carcinogenesis of colorectal carcinoma. Virchows Arch 426: 215–222

    Google Scholar 

  35. Rüschoff J, Roggendorf B, Brasch F et al. (2004) Molecular pathology in hereditary colorectal cancer. Recommendations of the Collaborative German Study Group on hereditary colorectal cancer funded by the German Cancer Aid (Deutsche Krebshilfe). Pathologe 25: 178–192

    Google Scholar 

  36. Slamon DJ, Leyland-Jones B, Shak S et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783–792

    Google Scholar 

  37. Sorlie T, Tibshirani R, Parker J et al. (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100: 8414–8423

    Google Scholar 

  38. Tamborini E, Bonadiman L, Greco A et al. (2004) A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 127: 294–299

    Google Scholar 

  39. Van’t Veer LJ, Dai H, Van de Vijver MJ et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530–536

    Google Scholar 

  40. Vasen HFA, Watson P, Mecklin JP, Lynch HT (1999) New clinical criteria for hereditary non-polyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC. Gastroenterology 116: 1453–1456

    Google Scholar 

  41. Wardelmann E, Losen I, Hans V et al. (2003) Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene indicates malignant histology and metastatic phenotype of gastrointestinal stromal tumors. Int J Cancer 106: 887–895

    Google Scholar 

  42. Wardelmann E, Thomas N, Merkelbach-Bruse S et al. (2005) Acquired resistance to imatinib in gastrointestinal stromal tumours caused by KIT mutations. Lancet Oncol 6: 249–251

    Google Scholar 

  43. Wixom CR, Albers EA, Weidner N (2004) HER-2 amplification: correlation of chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization. Appl Immunohistochem Mol Morphol 12: 248–251

    Google Scholar 

Download references

Interessenkonflikt:

Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen.

Author information

Authors and Affiliations

  1. Institut für Pathologie, Universitätsklinikum Bonn

    S. Merkelbach-Bruse & R. Büttner

  2. Institut für Pathologie, Universitätsklinikum Bonn, Sigmund-Freud-Straße 25, 53127 , Bonn

    S. Merkelbach-Bruse

Authors
  1. S. Merkelbach-Bruse
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Büttner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Merkelbach-Bruse.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Merkelbach-Bruse, S., Büttner, R. Molekulare Diagnostik bei nicht-hämatologischen malignen Erkrankungen. Onkologe 11, 873–888 (2005). https://doi.org/10.1007/s00761-005-0917-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-005-0917-2

Schlüsselwörter

Keywords

Search

Navigation